Approval · Notice of Compliance 31278 · 2023
FEBUXOSTAT: Notice of Compliance 31278
Issued July 21, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31278
- Date
- July 21, 2023
- Company
- Sanis Health Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement Between Two Manufacturers
- Canadian reference product
- ULORIC (Takeda Canada Incorporated)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FEBUXOSTAT | 02539837 | Marketed |
Medicinal ingredients
- FEBUXOSTAT 80 MG per TAB